Alpha Tau Medical (NASDAQ: DRTS) is an oncology-focused medical technology company developing alpha-radiation therapies designed to target and destroy solid tumors while minimizing damage to surrounding healthy tissue. The company’s proprietary Alpha DaRT technology represents a novel approach to cancer treatment and is being evaluated across multiple clinical applications.

Topics discussed include the company’s technology platform, clinical development efforts, business strategy, growth initiatives, market opportunities, and long-term outlook.

This company webcast was recorded during the Lytham Partners Spring 2026 Investor Conference